MX2020002241A - Anticuerpos anti-tm4sf y métodos de uso de los mismos. - Google Patents
Anticuerpos anti-tm4sf y métodos de uso de los mismos.Info
- Publication number
- MX2020002241A MX2020002241A MX2020002241A MX2020002241A MX2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A MX 2020002241 A MX2020002241 A MX 2020002241A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- antibodies
- tm4sf1
- tm4sf1 antibodies
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000055561 human TM4SF1 Human genes 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550994P | 2017-08-28 | 2017-08-28 | |
| PCT/US2018/048402 WO2019046338A1 (en) | 2017-08-28 | 2018-08-28 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002241A true MX2020002241A (es) | 2020-09-03 |
Family
ID=65526015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002241A MX2020002241A (es) | 2017-08-28 | 2018-08-28 | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11208495B2 (enExample) |
| EP (1) | EP3675906A4 (enExample) |
| JP (2) | JP7241080B2 (enExample) |
| CN (1) | CN111565750B (enExample) |
| AU (1) | AU2018323470B2 (enExample) |
| CA (1) | CA3074111A1 (enExample) |
| MX (1) | MX2020002241A (enExample) |
| WO (1) | WO2019046338A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091698A1 (en) | 2015-11-24 | 2017-06-01 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia |
| KR102612531B1 (ko) | 2016-11-17 | 2023-12-12 | 코그니토 쎄라퓨틱스, 인코포레이티드 | 인지 기능 개선을 위한 시스템 |
| JP7241080B2 (ja) * | 2017-08-28 | 2023-03-16 | アンジーエックス・インコーポレーテッド | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
| WO2019074637A1 (en) | 2017-10-10 | 2019-04-18 | Massachusetts Institute Of Technology | SYSTEMS AND METHODS FOR PREVENTION, MITIGATION AND / OR TREATMENT OF DEMENTIA |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| US12428477B2 (en) | 2019-02-27 | 2025-09-30 | Angiex, Inc. | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same |
| CN110734494B (zh) * | 2019-10-30 | 2021-04-30 | 上海市第一人民医院 | 抗tspan8单克隆抗体及其用途 |
| EP4126042A2 (en) * | 2020-03-27 | 2023-02-08 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2021222783A1 (en) * | 2020-05-01 | 2021-11-04 | Angiex, Inc. | Anti-tm4sf1 antibody drug conjugates and methods of using same |
| EP4188449A4 (en) * | 2020-07-31 | 2025-12-17 | Angiex Inc | ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH |
| AU2022242927A1 (en) * | 2021-03-26 | 2023-10-05 | Angiex, Inc. | Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same |
| EP4313009A4 (en) * | 2021-03-26 | 2025-12-10 | Angiex Inc | Maytansin-antibodies conjugate and their methods of use |
| KR102840561B1 (ko) * | 2021-06-03 | 2025-08-01 | 주식회사 메드팩토 | Tm4sf19 억제제 및 이의 용도 |
| WO2022255401A1 (ja) * | 2021-06-03 | 2022-12-08 | 国立大学法人 東京大学 | Ｅｒｋ－ｍａｐｋ経路の異常な活性化に伴い発現する疾患マーカー |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU2003225669A1 (en) | 2002-09-26 | 2004-04-19 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
| WO2010073694A1 (ja) * | 2008-12-25 | 2010-07-01 | 国立大学法人東京大学 | 抗tm4sf20抗体を用いた癌の診断と治療 |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| KR20140059168A (ko) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
| CN102590531A (zh) * | 2012-03-24 | 2012-07-18 | 广西壮族自治区肿瘤防治研究所 | 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法 |
| JP6534654B2 (ja) * | 2013-10-10 | 2019-06-26 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法 |
| HRP20210957T1 (hr) | 2013-11-22 | 2021-09-17 | Sabre Therapeutics Llc | Spojevi inhibitori autotaksina |
| TW202132337A (zh) * | 2014-05-28 | 2021-09-01 | 美商艾吉納斯公司 | 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法 |
| JP7241080B2 (ja) * | 2017-08-28 | 2023-03-16 | アンジーエックス・インコーポレーテッド | 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法 |
-
2018
- 2018-08-28 JP JP2020534793A patent/JP7241080B2/ja active Active
- 2018-08-28 EP EP18849908.1A patent/EP3675906A4/en active Pending
- 2018-08-28 CN CN201880070504.7A patent/CN111565750B/zh active Active
- 2018-08-28 WO PCT/US2018/048402 patent/WO2019046338A1/en not_active Ceased
- 2018-08-28 MX MX2020002241A patent/MX2020002241A/es unknown
- 2018-08-28 US US16/642,995 patent/US11208495B2/en active Active
- 2018-08-28 AU AU2018323470A patent/AU2018323470B2/en active Active
- 2018-08-28 CA CA3074111A patent/CA3074111A1/en active Pending
-
2021
- 2021-11-22 US US17/532,664 patent/US20220153860A1/en not_active Abandoned
- 2021-11-22 US US17/532,660 patent/US20220267461A1/en not_active Abandoned
-
2023
- 2023-03-06 JP JP2023033463A patent/JP2023071888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019046338A1 (en) | 2019-03-07 |
| EP3675906A4 (en) | 2021-05-26 |
| CN111565750B (zh) | 2023-11-03 |
| JP7241080B2 (ja) | 2023-03-16 |
| AU2018323470A1 (en) | 2020-03-19 |
| US20220153860A1 (en) | 2022-05-19 |
| US20220267461A1 (en) | 2022-08-25 |
| EP3675906A1 (en) | 2020-07-08 |
| CA3074111A1 (en) | 2019-03-07 |
| JP2023071888A (ja) | 2023-05-23 |
| US11208495B2 (en) | 2021-12-28 |
| US20200270360A1 (en) | 2020-08-27 |
| AU2018323470B2 (en) | 2025-04-24 |
| CN111565750A (zh) | 2020-08-21 |
| JP2020534351A (ja) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002241A (es) | Anticuerpos anti-tm4sf y métodos de uso de los mismos. | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
| JOP20190236A1 (ar) | أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| SG10201809668TA (en) | Anti-her2 antibodies and immunoconjugates | |
| MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| TN2016000559A1 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
| SG10201804931QA (en) | Anti-cll-1 antibodies and immunoconjugates | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
| PH12018500710A1 (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
| MX2018008592A (es) | Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos. | |
| PH12018502502A1 (en) | Anti-gitr antibodies and uses thereof | |
| SG10201900571YA (en) | Anti-pd-1 antibodies | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof |